Exenatide: pharmacokinetics, clinical use, and future directions.

Abstract

INTRODUCTION The first-in-class glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide, which was initially approved in 2005, is available in twice-daily (BID) and once-weekly (QW) formulations. Clinical trial data suggest both formulations are effective and safe for patients with type 2 diabetes (T2D), both as monotherapy and as part of combination… (More)
DOI: 10.1080/14656566.2017.1282463

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.